Burkitt Lymphoma

Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma with rapid tumor growth and frequent abdominal, jaw, or CNS involvement. Escalate suspected disease immediately to a lymphoma-directed hematology-oncology team; do not use a prolonged diagnostic observation interval when imaging or clinical trajectory suggests rapidly progressive disease. The Lancet+1The LancetDiagnosis and treatment of Burkitt lymphoma in adultsPubMedBurkitt Lymphoma - StatPearls - NCBI Bookshelf

Obtain adequate tissue for morphology, immunophenotyping, and cytogenetic or molecular testing for MYC rearrangement. MYC rearrangements are considered universal in Burkitt lymphoma, including HIV-associated disease, but MYC-rearranged aggressive B-cell neoplasms also include entities with clinicopathologic features distinct from Burkitt lymphoma. A pathology conclusion of Burkitt lymphoma should therefore integrate morphology with the exclusion of high-grade B-cell lymphoma, not otherwise specified, and other MYC-rearranged high-grade B-cell lymphomas rather than relying on MYC testing alone. ScienceDirect+3ScienceDirectHIV-associated Burkitt lymphoma - ScienceDirectASHMYC rearrangements in high-grade B-cell lymphoma with ...ASHHigh-grade B-cell lymphoma, not otherwise specifiedASHDiagnosis of 'double hit' diffuse large B-cell lymphoma and B ...

During diagnostic acceleration, evaluate symptoms or signs of bowel compromise, bulky abdominal disease, neurologic involvement, and high tumor burden because these findings affect treatment setting and CNS evaluation. Burkitt lymphoma is associated with high cell turnover and extensive FDG avidity; FDG-PET/CT is routinely used for staging, although the prognostic role of response PET remains less certain. Wolters KluwerWolters KluwerAbstracts : Indian Journal of Nuclear Medicine

Perform systemic staging with FDG-PET/CT and obtain marrow evaluation when clinically indicated for disease definition. In the multicenter risk-adapted DA-EPOCH-R study, pretreatment CSF flow cytometry was incorporated specifically to identify CSF involvement and guide intrathecal methotrexate intensity. Wolters Kluwer+1Wolters KluwerAbstracts : Indian Journal of Nuclear MedicinePubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

Obtain cerebrospinal fluid for cytology and flow cytometry before systemic therapy when safely feasible, particularly when there are neurologic findings or substantial systemic disease. A positive CSF assessment changes management from prophylactic to active CNS-directed treatment in the DA-EPOCH-R approach. PubMedPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

Do not equate absence of neurologic symptoms with absence of CNS risk. Intensive Burkitt regimens incorporate CNS prophylaxis because CNS relapse prevention is a core treatment requirement; the major exception in the risk-adapted DA-EPOCH-R trial was a prespecified low-risk group treated without CNS prophylaxis. Wiley+2WileyLymphoma - Tsang - Major Reference WorksPubMedBurkitt Lymphoma - StatPearls - NCBI BookshelfPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

Marrow or peripheral blood involvement identifies a higher-risk subgroup in the DA-EPOCH-R study. Among high-risk patients without CSF involvement, 4-year event-free survival was 66.7% with marrow or peripheral involvement versus 92.4% without either finding, supporting explicit documentation of these sites before finalizing risk discussions and treatment intensity. PubMedPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

Plan initial treatment in a setting capable of frequent clinical and laboratory reassessment when disease burden is high or metabolic instability is anticipated. The high cellular turnover of Burkitt lymphoma and the high-intensity regimens used for treatment make tumor lysis planning and early monitoring operational priorities; DA-EPOCH-R has been described as feasible in an outpatient setting, including often during cycle 1, because of a low reported tumor-lysis risk in that strategy. Wolters Kluwer+1Wolters KluwerAbstracts : Indian Journal of Nuclear MedicineASCOMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma | Journal of Clinical Oncology

Before selecting a dose-intensive regimen, assess physiologic tolerance and the likelihood of infectious and hematologic toxicity. High-intensity Burkitt regimens carry significant hematologic toxicity and severe infection risk; older adults and patients with HIV more often require dose modifications with highly dose-intensive treatment. PubMed+1PubMedBurkitt Lymphoma - StatPearls - NCBI BookshelfPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

For HIV-associated Burkitt lymphoma, do not substitute a less effective approach solely because HIV is present. High-dose chemotherapy has become feasible in the antiretroviral era, and CODOX-M/IVAC with rituximab has been reported to allow excellent immunologic recovery in HIV-associated Burkitt lymphoma. Regimen selection should still account for immune status, systemic disease, CNS involvement, and anticipated treatment tolerance. Wiley+3WileyDose‐intensive chemotherapy including rituximab in Burkitt's ...WileyBritish HIV Association guidelines for ...ScienceDirectHIV-associated Burkitt lymphoma - ScienceDirectPubMedBurkitt Lymphoma - StatPearls - NCBI Bookshelf

Use rituximab-containing multiagent chemoimmunotherapy as the treatment backbone. A randomized adult study found that adding rituximab to highly dose-intensive chemotherapy improved 3-year event-free survival to 75% (95% CI, 66% to 82%) versus 62% (95% CI, 53% to 70%) with chemotherapy alone. Wiley+1WileyTargeted therapy in Burkitt lymphoma: Small molecule ...ASCOMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma | Journal of Clinical Oncology

CODOX-M/IVAC is a commonly cited intensive regimen for Burkitt lymphoma, and CNS prophylaxis is required in this treatment framework. Its clinical tradeoff is established activity against the substantial acute toxicity burden of high-intensity chemotherapy, including hematologic toxicity and severe infection. The Lancet+2The LancetSupplementary appendixWileyLymphoma - Tsang - Major Reference WorksPubMedBurkitt Lymphoma - StatPearls - NCBI Bookshelf

Risk-adapted DA-EPOCH-R is an adult alternative with prospective multicenter data. High-risk patients received six cycles, with rituximab on day 1, and underwent PET after two cycles. Those without CNS involvement received intrathecal methotrexate on days 1 and 5 of cycles 3 through 6; patients with CSF involvement received active CNS therapy. PubMedPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

Do not use treatment response imaging alone to de-escalate CNS-directed care outside the regimen-specific approach. The cited DA-EPOCH-R protocol used baseline CSF flow cytometry to determine intrathecal treatment intensity and used interim PET after cycle 2 in high-risk disease; this is a structured risk-adapted pathway rather than evidence that PET replaces CNS staging. ASCO+1ASCOMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma | Journal of Clinical OncologyPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

During therapy, monitor for hematologic toxicity and severe infection, the principal adverse-effect categories associated with high-intensity Burkitt regimens. Dose-intensive therapy in older adults and in patients with HIV may require modification, but modification should follow an explicit reassessment of toxicity and treatment tolerance rather than routine preemptive de-intensification. PubMed+1PubMedBurkitt Lymphoma - StatPearls - NCBI BookshelfPubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

If using the high-risk DA-EPOCH-R pathway, obtain PET after two cycles as specified in the multicenter protocol. Interpret interim imaging within the planned regimen and alongside clinical status and marrow or CSF findings; the evidence excerpt identifies PET as a staging modality and protocol response assessment but does not establish PET as a replacement for direct CNS or marrow evaluation. Wolters Kluwer+1Wolters KluwerAbstracts : Indian Journal of Nuclear MedicinePubMedMulticenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma - PMC

Counsel survivors that durable remission is strongly associated with remaining event-free through the first year in endemic Burkitt lymphoma, where relapse risk after one year is reported as 5% or less. This time-based estimate should not be generalized without qualification to every adult sporadic or HIV-associated population, but it supports concentrated clinical vigilance early after treatment completion. PubMedPubMedBurkitt Lymphoma - StatPearls - NCBI Bookshelf